NCT03606395 - Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 6, 2018

Primary Completion Date

June 9, 2019

Study Completion Date

July 7, 2019

Conditions

Treatment Resistant Depression

Interventions

DRUG

NV-5138

single ascending dose

DRUG

Placebos

Placebo liquid solution to mimic NV-5138

Trial Locations (9)

MD Clinical, Hallandale

Innovative Clinical Research Inc, Hialeah

Research Centers of America, Hollywood

University of Alabama at Birmingham, Birmingham

Midwest Clinical Research, Dayton

St. Louis Clinical Trials, St Louis

Collaborative Neuroscience Network, Long Beach

Synergy San Diego, San Diego

Hassman Research Institute, Berlin